Policosanol

Summary

Policosanol (CHEMBL3707352) is a phase-3 clinical-stage small molecule (ATC C10AX08); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C10AX08
• Indications: 1 condition
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707352
Name	Policosanol
Type	Small molecule
Max phase	3
ATC	C10AX08

Also known as: Policosanol, POLICOSANOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
Not specified	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05365425	PHASE4	RECRUITING	Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
NCT00288483	PHASE3	TERMINATED	Cholesterol-Lowering Effects of Policosanol
NCT02543099	PHASE3	UNKNOWN	Efficacy and Safety Study of Policosanol
NCT00312923	PHASE2	COMPLETED	Preliminary Study of Safety and Efficacy of Policosanol
NCT00510809	Not specified	COMPLETED	Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy
NCT00654459	Not specified	COMPLETED	Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).